Annual report [Section 13 and 15(d), not S-K Item 405]

Fair Value of Financial Instruments - Narrative (Details)

v3.25.4
Fair Value of Financial Instruments - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Feb. 25, 2025
Sep. 30, 2021
Subsidiary, Sale of Stock [Line Items]        
Warrants outstanding (in shares) 2,633,195 7,732,168 5,098,978  
Increase (decrease) in fair value $ (16,109) $ 51,960    
Common Stock        
Subsidiary, Sale of Stock [Line Items]        
Common issued for warrants exercised (in shares) 9,499,138      
Private Warrants        
Subsidiary, Sale of Stock [Line Items]        
Warrants outstanding (in shares) 2,633,195 7,732,168   7,732,168
Number of warrants to purchase common stock (in shares)       1
Fair value (in dollars per share)       $ 11.50
Increase (decrease) in fair value $ (16,109) $ 51,960    
Fair value, liability, recurring basis, unobservable input reconciliation, gain (loss), statement of income or comprehensive income   Other Nonoperating Income (Expense)    
Class of warrants exercised (in shares) 4,631,799      
Warrants exercised (in shares) 467,174      
Proceeds from warrant exercises $ 5,400      
Private Warrants | Common Stock        
Subsidiary, Sale of Stock [Line Items]        
Common issued for warrants exercised (in shares) 2,293,739      
Warrants exercised (in shares) 467,174